Asset Acquisition, Share Price

No definition available.

Name:	bmy_AssetAcquisitionSharePrice
Namespace Prefix:	bmy_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Contingent and Regulatory Milestone Payments, Maximum Aggregate

+ References

No definition available.

+ Details

Name:	bmy_ContingentAndRegulatoryMilestonePaymentsMaximumAggregate
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License and Other Arrangements Anniversary Payments

+ References

No definition available.

+ Details

Name:	bmy_LicenseAndOtherArrangementsAnniversaryPayments
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License and Other Arrangements, Number Of Assets Developed

+ References

No definition available.

+ Details

Name:	bmy_LicenseAndOtherArrangementsNumberOfAssetsDeveloped
Namespace Prefix:	bmy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

License and Other Arrangements Upfront Payments

+ References

No definition available.

+ Details

Name:	bmy_LicenseAndOtherArrangementsUpfrontPayments
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Licensing Arrangements

+ References

No definition available.

+ Details

Name:	bmy_LicensingArrangementsLineItems
Namespace Prefix:	bmy_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment And Royalty Allocation

+ References

No definition available.

+ Details

Name:	bmy_PaymentAndRoyaltyAllocation
Namespace Prefix:	bmy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Payments to Acquire Productive Assets, Net Of Cash Acquired

+ References

No definition available.

+ Details

Name:	bmy_PaymentsToAcquireProductiveAssetsNetOfCashAcquired
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage Of Net Sales Payable To Alliance Partner

+ References

No definition available.

+ Details

Name:	bmy_PercentageOfNetSalesPayableToAlliancePartner
Namespace Prefix:	bmy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_AssetAcquisitionAxis=bmy_A2seventyBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bmy_LicensingAndOtherArrangementsAxis=bmy_KeytrudaRoyaltiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bmy_BristolMyersSquibbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bmy_OnoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bmy_LicensingAndOtherArrangementsAxis=bmy_HengruiLicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bmy_HengruiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bmy_LicensingAndOtherArrangementsAxis=bmy_PriorityReviewVoucherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bmy_LicensingAndOtherArrangementsAxis=bmy_ReblozylLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bmy_MerckMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bmy_LicensingAndOtherArrangementsAxis=bmy_WinrevairLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_DiabetesBusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Narrative (Details) $ / shares in Units, $ in Millions		3 Months Ended				6 Months Ended		12 Months Ended		36 Months Ended
	May 13, 2025 USD ($) $ / shares	Sep. 30, 2026 USD ($)	Jun. 30, 2026 USD ($)	Mar. 31, 2026	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2028 USD ($)	Dec. 31, 2027 USD ($)	Dec. 31, 2026	May 31, 2026 assetDeveloped
Licensing Arrangements [Line Items]
Research and development			$ 2,959		$ 2,580	$ 5,608	$ 4,837
2seventy bio
Licensing Arrangements [Line Items]
Asset acquisition, share price (in dollars per share) \| $ / shares	$ 5.00
Payments to acquire assets	$ 287
Payments for asset acquisitions, net of cash acquired	$ 114
Keytruda royalties \| Forecast
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner										2.50%
Keytruda royalties \| Forecast \| Bristol-Myers Squibb
Licensing Arrangements [Line Items]
Payment and royalty allocation										75.00%
Keytruda royalties \| Forecast \| Ono
Licensing Arrangements [Line Items]
Payment and royalty allocation										25.00%
Hengrui License Agreements \| Hengrui
Licensing Arrangements [Line Items]
Assets developed \| assetDeveloped											13
Hengrui License Agreements \| Forecast \| Hengrui
Licensing Arrangements [Line Items]
License and other arrangements upfront payments		$ 600
License and other arrangements anniversary payments								$ 175	$ 175
Maximum aggregate contingent and regulatory milestone payments								$ 14,300
Priority Review Voucher
Licensing Arrangements [Line Items]
Research and development			220
Reblozyl License \| Merck
Licensing Arrangements [Line Items]
Royalty expense			165		122	$ 289	228
Reblozyl License \| Merck \| Minimum
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner						20.00%
Reblozyl License \| Merck \| Maximum
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner						24.00%
Winrevair* License \| Merck
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner						22.00%
Royalty expense			$ 131		$ 78	$ 255	$ 124
Diabetes business - royalties
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner				14.00%